HIV capsid inhibition (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "HIV capsid inhibition" in English language version.

refsWebsite

Global rank English rank

26nih.gov

4^th place

15doi.org

2^nd place

4harvard.edu

18^th place

17^th place

2web.archive.org

1^st place

2canada.ca

1,712^th place

1,063^rd place

1europa.eu

68^th place

117^th place

1fda.gov

447^th place

338^th place

1semanticscholar.org

11^th place

8^th place

canada.ca

health-products.canada.ca

"Sunlenca Product information (oral)". Health Canada. 25 April 2012. Retrieved 23 December 2022.
"Sunlenca Product information (subcutaneous)". Health Canada. 25 April 2012. Retrieved 23 December 2022.

doi.org

McFadden WM, Snyder AA, Kirby KA, Tedbury PR, Raj M, Wang Z, Sarafianos SG (December 2021). "Rotten to the core: antivirals targeting the HIV-1 capsid core". Retrovirology. 18 (1): 41. doi:10.1186/s12977-021-00583-z. PMC 8693499. PMID 34937567.
Isel C, Ehresmann C, Marquet R (January 2010). "Initiation of HIV Reverse Transcription". Viruses. 2 (1): 213–243. doi:10.3390/v2010213. PMC 3185550. PMID 21994608.
Pornillos O, Ganser-Pornillos BK, Yeager M (January 2011). "Atomic-level modelling of the HIV capsid". Nature. 469 (7330): 424–427. Bibcode:2011Natur.469..424P. doi:10.1038/nature09640. PMC 3075868. PMID 21248851.
Ambrose Z, Aiken C (April 2014). "HIV-1 uncoating: connection to nuclear entry and regulation by host proteins". Virology. 454–455: 371–379. doi:10.1016/j.virol.2014.02.004. PMC 3988234. PMID 24559861.
Hitchcock, Allison M.; Kufel, Wesley D.; Dwyer, Keri A. Mastro; Sidman, Eric F. (January 2024). "Lenacapavir: A novel injectable HIV-1 capsid inhibitor". International Journal of Antimicrobial Agents. 63 (1): 107009. doi:10.1016/j.ijantimicag.2023.107009.
Bester SM, Wei G, Zhao H, Adu-Ampratwum D, Iqbal N, Courouble VV, et al. (October 2020). "Structural and mechanistic bases for a potent HIV-1 capsid inhibitor". Science. 370 (6514): 360–364. Bibcode:2020Sci...370..360B. doi:10.1126/science.abb4808. PMC 7831379. PMID 33060363.
Thenin-Houssier S, de Vera IM, Pedro-Rosa L, Brady A, Richard A, Konnick B, et al. (April 2016). "Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication". Antimicrobial Agents and Chemotherapy. 60 (4): 2195–2208. doi:10.1128/AAC.02574-15. PMC 4808204. PMID 26810656.
Tang C, Loeliger E, Kinde I, Kyere S, Mayo K, Barklis E, et al. (April 2003). "Antiviral inhibition of the HIV-1 capsid protein". Journal of Molecular Biology. 327 (5): 1013–1020. doi:10.1016/S0022-2836(03)00289-4. PMID 12662926.
Carnes, Stephanie K.; Sheehan, Jonathan H.; Aiken, Christopher (July 2018). "Inhibitors of the HIV-1 capsid, a target of opportunity". Current Opinion in HIV and AIDS. 13 (4): 359–365. doi:10.1097/COH.0000000000000472. PMC 6075716.
Blair WS, Pickford C, Irving SL, Brown DG, Anderson M, Bazin R, et al. (December 2010). Luban J (ed.). "HIV capsid is a tractable target for small molecule therapeutic intervention". PLOS Pathogens. 6 (12): e1001220. doi:10.1371/journal.ppat.1001220. PMC 3000358. PMID 21170360.
Yant SR, Mulato A, Hansen D, Tse WC, Niedziela-Majka A, Zhang JR, et al. (September 2019). "A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model". Nature Medicine. 25 (9): 1377–1384. doi:10.1038/s41591-019-0560-x. PMC 7396128. PMID 31501601.
Sticht J, Humbert M, Findlow S, Bodem J, Müller B, Dietrich U, et al. (August 2005). "A peptide inhibitor of HIV-1 assembly in vitro". Nature Structural & Molecular Biology. 12 (8): 671–677. doi:10.1038/nsmb964. PMID 16041387. S2CID 5953442.
Bocanegra R, Nevot M, Doménech R, López I, Abián O, Rodríguez-Huete A, et al. (2011-09-08). "Rationally designed interfacial peptides are efficient in vitro inhibitors of HIV-1 capsid assembly with antiviral activity". PLOS ONE. 6 (9): e23877. Bibcode:2011PLoSO...623877B. doi:10.1371/journal.pone.0023877. PMC 3169566. PMID 21931621.
Zhang H, Zhao Q, Bhattacharya S, Waheed AA, Tong X, Hong A, et al. (May 2008). "A cell-penetrating helical peptide as a potential HIV-1 inhibitor". Journal of Molecular Biology. 378 (3): 565–580. doi:10.1016/j.jmb.2008.02.066. PMC 2695608. PMID 18374356.
Ramesh D, Mohanty AK, De A, Vijayakumar BG, Sethumadhavan A, Muthuvel SK, et al. (June 2022). "Uracil derivatives as HIV-1 capsid protein inhibitors: design, in silico, in vitro and cytotoxicity studies". RSC Advances. 12 (27): 17466–17480. Bibcode:2022RSCAd..1217466R. doi:10.1039/D2RA02450K. PMC 9190787. PMID 35765450.

europa.eu

ema.europa.eu

"Sunlenca EPAR". European Medicines Agency (EMA). 22 June 2022. Archived from the original on 26 August 2022. Retrieved 25 August 2022.

fda.gov

"FDA Approves New HIV Drug for Adults with Limited Treatment Options" (Press release). U.S. Food and Drug Administration (FDA). 22 December 2022. Archived from the original on 2 February 2024. This article incorporates text from this source, which is in the public domain.

harvard.edu

ui.adsabs.harvard.edu

Pornillos O, Ganser-Pornillos BK, Yeager M (January 2011). "Atomic-level modelling of the HIV capsid". Nature. 469 (7330): 424–427. Bibcode:2011Natur.469..424P. doi:10.1038/nature09640. PMC 3075868. PMID 21248851.
Bester SM, Wei G, Zhao H, Adu-Ampratwum D, Iqbal N, Courouble VV, et al. (October 2020). "Structural and mechanistic bases for a potent HIV-1 capsid inhibitor". Science. 370 (6514): 360–364. Bibcode:2020Sci...370..360B. doi:10.1126/science.abb4808. PMC 7831379. PMID 33060363.
Bocanegra R, Nevot M, Doménech R, López I, Abián O, Rodríguez-Huete A, et al. (2011-09-08). "Rationally designed interfacial peptides are efficient in vitro inhibitors of HIV-1 capsid assembly with antiviral activity". PLOS ONE. 6 (9): e23877. Bibcode:2011PLoSO...623877B. doi:10.1371/journal.pone.0023877. PMC 3169566. PMID 21931621.
Ramesh D, Mohanty AK, De A, Vijayakumar BG, Sethumadhavan A, Muthuvel SK, et al. (June 2022). "Uracil derivatives as HIV-1 capsid protein inhibitors: design, in silico, in vitro and cytotoxicity studies". RSC Advances. 12 (27): 17466–17480. Bibcode:2022RSCAd..1217466R. doi:10.1039/D2RA02450K. PMC 9190787. PMID 35765450.

nih.gov

pubmed.ncbi.nlm.nih.gov

McFadden WM, Snyder AA, Kirby KA, Tedbury PR, Raj M, Wang Z, Sarafianos SG (December 2021). "Rotten to the core: antivirals targeting the HIV-1 capsid core". Retrovirology. 18 (1): 41. doi:10.1186/s12977-021-00583-z. PMC 8693499. PMID 34937567.
Isel C, Ehresmann C, Marquet R (January 2010). "Initiation of HIV Reverse Transcription". Viruses. 2 (1): 213–243. doi:10.3390/v2010213. PMC 3185550. PMID 21994608.
Pornillos O, Ganser-Pornillos BK, Yeager M (January 2011). "Atomic-level modelling of the HIV capsid". Nature. 469 (7330): 424–427. Bibcode:2011Natur.469..424P. doi:10.1038/nature09640. PMC 3075868. PMID 21248851.
Ambrose Z, Aiken C (April 2014). "HIV-1 uncoating: connection to nuclear entry and regulation by host proteins". Virology. 454–455: 371–379. doi:10.1016/j.virol.2014.02.004. PMC 3988234. PMID 24559861.
Bester SM, Wei G, Zhao H, Adu-Ampratwum D, Iqbal N, Courouble VV, et al. (October 2020). "Structural and mechanistic bases for a potent HIV-1 capsid inhibitor". Science. 370 (6514): 360–364. Bibcode:2020Sci...370..360B. doi:10.1126/science.abb4808. PMC 7831379. PMID 33060363.
Thenin-Houssier S, de Vera IM, Pedro-Rosa L, Brady A, Richard A, Konnick B, et al. (April 2016). "Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication". Antimicrobial Agents and Chemotherapy. 60 (4): 2195–2208. doi:10.1128/AAC.02574-15. PMC 4808204. PMID 26810656.
Tang C, Loeliger E, Kinde I, Kyere S, Mayo K, Barklis E, et al. (April 2003). "Antiviral inhibition of the HIV-1 capsid protein". Journal of Molecular Biology. 327 (5): 1013–1020. doi:10.1016/S0022-2836(03)00289-4. PMID 12662926.
Blair WS, Pickford C, Irving SL, Brown DG, Anderson M, Bazin R, et al. (December 2010). Luban J (ed.). "HIV capsid is a tractable target for small molecule therapeutic intervention". PLOS Pathogens. 6 (12): e1001220. doi:10.1371/journal.ppat.1001220. PMC 3000358. PMID 21170360.
Yant SR, Mulato A, Hansen D, Tse WC, Niedziela-Majka A, Zhang JR, et al. (September 2019). "A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model". Nature Medicine. 25 (9): 1377–1384. doi:10.1038/s41591-019-0560-x. PMC 7396128. PMID 31501601.
Sticht J, Humbert M, Findlow S, Bodem J, Müller B, Dietrich U, et al. (August 2005). "A peptide inhibitor of HIV-1 assembly in vitro". Nature Structural & Molecular Biology. 12 (8): 671–677. doi:10.1038/nsmb964. PMID 16041387. S2CID 5953442.
Bocanegra R, Nevot M, Doménech R, López I, Abián O, Rodríguez-Huete A, et al. (2011-09-08). "Rationally designed interfacial peptides are efficient in vitro inhibitors of HIV-1 capsid assembly with antiviral activity". PLOS ONE. 6 (9): e23877. Bibcode:2011PLoSO...623877B. doi:10.1371/journal.pone.0023877. PMC 3169566. PMID 21931621.
Zhang H, Zhao Q, Bhattacharya S, Waheed AA, Tong X, Hong A, et al. (May 2008). "A cell-penetrating helical peptide as a potential HIV-1 inhibitor". Journal of Molecular Biology. 378 (3): 565–580. doi:10.1016/j.jmb.2008.02.066. PMC 2695608. PMID 18374356.
Ramesh D, Mohanty AK, De A, Vijayakumar BG, Sethumadhavan A, Muthuvel SK, et al. (June 2022). "Uracil derivatives as HIV-1 capsid protein inhibitors: design, in silico, in vitro and cytotoxicity studies". RSC Advances. 12 (27): 17466–17480. Bibcode:2022RSCAd..1217466R. doi:10.1039/D2RA02450K. PMC 9190787. PMID 35765450.

ncbi.nlm.nih.gov

McFadden WM, Snyder AA, Kirby KA, Tedbury PR, Raj M, Wang Z, Sarafianos SG (December 2021). "Rotten to the core: antivirals targeting the HIV-1 capsid core". Retrovirology. 18 (1): 41. doi:10.1186/s12977-021-00583-z. PMC 8693499. PMID 34937567.
Isel C, Ehresmann C, Marquet R (January 2010). "Initiation of HIV Reverse Transcription". Viruses. 2 (1): 213–243. doi:10.3390/v2010213. PMC 3185550. PMID 21994608.
Pornillos O, Ganser-Pornillos BK, Yeager M (January 2011). "Atomic-level modelling of the HIV capsid". Nature. 469 (7330): 424–427. Bibcode:2011Natur.469..424P. doi:10.1038/nature09640. PMC 3075868. PMID 21248851.
Ambrose Z, Aiken C (April 2014). "HIV-1 uncoating: connection to nuclear entry and regulation by host proteins". Virology. 454–455: 371–379. doi:10.1016/j.virol.2014.02.004. PMC 3988234. PMID 24559861.
Bester SM, Wei G, Zhao H, Adu-Ampratwum D, Iqbal N, Courouble VV, et al. (October 2020). "Structural and mechanistic bases for a potent HIV-1 capsid inhibitor". Science. 370 (6514): 360–364. Bibcode:2020Sci...370..360B. doi:10.1126/science.abb4808. PMC 7831379. PMID 33060363.
Thenin-Houssier S, de Vera IM, Pedro-Rosa L, Brady A, Richard A, Konnick B, et al. (April 2016). "Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication". Antimicrobial Agents and Chemotherapy. 60 (4): 2195–2208. doi:10.1128/AAC.02574-15. PMC 4808204. PMID 26810656.
Carnes, Stephanie K.; Sheehan, Jonathan H.; Aiken, Christopher (July 2018). "Inhibitors of the HIV-1 capsid, a target of opportunity". Current Opinion in HIV and AIDS. 13 (4): 359–365. doi:10.1097/COH.0000000000000472. PMC 6075716.
Blair WS, Pickford C, Irving SL, Brown DG, Anderson M, Bazin R, et al. (December 2010). Luban J (ed.). "HIV capsid is a tractable target for small molecule therapeutic intervention". PLOS Pathogens. 6 (12): e1001220. doi:10.1371/journal.ppat.1001220. PMC 3000358. PMID 21170360.
Yant SR, Mulato A, Hansen D, Tse WC, Niedziela-Majka A, Zhang JR, et al. (September 2019). "A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model". Nature Medicine. 25 (9): 1377–1384. doi:10.1038/s41591-019-0560-x. PMC 7396128. PMID 31501601.
Bocanegra R, Nevot M, Doménech R, López I, Abián O, Rodríguez-Huete A, et al. (2011-09-08). "Rationally designed interfacial peptides are efficient in vitro inhibitors of HIV-1 capsid assembly with antiviral activity". PLOS ONE. 6 (9): e23877. Bibcode:2011PLoSO...623877B. doi:10.1371/journal.pone.0023877. PMC 3169566. PMID 21931621.
Zhang H, Zhao Q, Bhattacharya S, Waheed AA, Tong X, Hong A, et al. (May 2008). "A cell-penetrating helical peptide as a potential HIV-1 inhibitor". Journal of Molecular Biology. 378 (3): 565–580. doi:10.1016/j.jmb.2008.02.066. PMC 2695608. PMID 18374356.
Ramesh D, Mohanty AK, De A, Vijayakumar BG, Sethumadhavan A, Muthuvel SK, et al. (June 2022). "Uracil derivatives as HIV-1 capsid protein inhibitors: design, in silico, in vitro and cytotoxicity studies". RSC Advances. 12 (27): 17466–17480. Bibcode:2022RSCAd..1217466R. doi:10.1039/D2RA02450K. PMC 9190787. PMID 35765450.

hivinfo.nih.gov

"FDA-Approved HIV Medicines | NIH". hivinfo.nih.gov. Retrieved 2023-05-25.

semanticscholar.org

api.semanticscholar.org

Sticht J, Humbert M, Findlow S, Bodem J, Müller B, Dietrich U, et al. (August 2005). "A peptide inhibitor of HIV-1 assembly in vitro". Nature Structural & Molecular Biology. 12 (8): 671–677. doi:10.1038/nsmb964. PMID 16041387. S2CID 5953442.

web.archive.org

"Sunlenca EPAR". European Medicines Agency (EMA). 22 June 2022. Archived from the original on 26 August 2022. Retrieved 25 August 2022.
"FDA Approves New HIV Drug for Adults with Limited Treatment Options" (Press release). U.S. Food and Drug Administration (FDA). 22 December 2022. Archived from the original on 2 February 2024. This article incorporates text from this source, which is in the public domain.